OPDP accuses Acorda of improperly marketing MS drug

08/12/2013 | PharmaLive.com

The FDA's Office of Prescription Drug Promotion issued a warning letter to Acorda Therapeutics, accusing it of omitting information on risks, adverse events and contraindications in a newspaper ad for the company's Ampyra multiple sclerosis drug. Acorda was warned last year that a video for the same drug overstated efficacy and minimized risk information.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX